Pharmaceuticals

Global Breast Cancer Gene (BRCA) Mutations Treatment Market Projected to Expand at 7% CAGR by 2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Size Likely To Evolve From 2025 Through 2034?

The market for treating breast cancer gene (BRCA) mutations has experienced significant expansion recently. Its value is projected to increase from $4.67 billion in 2024 to $5.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.4%. This historical growth can be linked to factors such as the expanded access to genetic testing, increased public and private investment in cancer research, a growing need for tailored medical treatments, wider acceptance of preventative health strategies, and a rise in at-risk individuals participating in screening programs.

The breast cancer gene (BRCA) mutations treatment market is anticipated to experience substantial growth over the next few years. It is projected to expand to $6.56 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period can be attributed to the increasing integration of genetic testing into insurance coverage, a growing demand for companion diagnostics, a heightened focus on hereditary cancer screening programs, an increase in clinical trials targeting BRCA-related cancers, and the rising adoption of risk-reducing surgical procedures. Prominent trends within the forecast period involve advancements in gene editing technologies, innovations in non-invasive diagnostic techniques, the integration of AI and machine learning in genetic risk assessment, further developments in liquid biopsy applications for BRCA-related cancers, and the emergence of innovative personalized treatment algorithms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Are The Main Drivers Boosting The Breast Cancer Gene (BRCA) Mutations Treatment Industry’s Expansion?

The future expansion of the breast cancer gene (BRCA) mutation treatment market is anticipated, driven by the growing need for targeted therapies. These medical interventions are designed to precisely attack cancer cells by concentrating on specific genetic mutations or proteins that contribute to tumor development. The increasing preference for targeted therapies stems largely from their capacity to pinpoint and attack disease-causing cells or molecules, thereby reducing harm to healthy tissues. This leads to enhanced treatment efficacy and a reduction in adverse effects when contrasted with conventional treatments. For breast cancer gene (BRCA) mutations, targeted therapies provide crucial support through precision medicines that directly address the underlying genetic changes causing the condition, thus enhancing patient outcomes and mitigating unwanted side effects. An illustration of this trend is seen in a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, published in July 2023. This report noted that by the close of Q1 2023, there were 247 gene therapies in Phase II, a figure that subsequently increased by 5% to reach 260 by the end of Q2 2023. Consequently, the expanding need for targeted therapies is a key factor propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.

What Are The Leading Segments Analyzed In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The breast cancer gene (BRCA) mutations treatment market covered in this report is segmented

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive Cell Transfer (ACT)

What Key Innovation Trends Are Fueling Advancements In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Leading companies within the breast cancer gene (BRCA) mutation treatment market are prioritizing the development of advanced solutions, such as adjuvant treatment, to enhance therapeutic and patient outcomes. Adjuvant treatment is a supplemental therapy administered after the primary treatment to eradicate any remaining cancer cells and mitigate the risk of recurrence, thereby improving overall treatment success and extending patient survival. For instance, in August 2022, AstraZeneca plc, a UK-based biotechnology company, and Merck & Co., Inc., a US-based pharmaceutical company, introduced LYNPARZA (olaparib), which secured European Commission approval for adult patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer. This approval enables LYNPARZA to be utilized as monotherapy or in combination with endocrine therapy for patients who have previously received neoadjuvant or adjuvant chemotherapy. The approval was granted based on findings from the phase 3 OlympiA trial, which showed a significant improvement in invasive disease-free survival and overall survival, considerably lowering the risk of breast cancer recurrence or death.

Which Key Market Players Are Investing In Expansion And Innovation Of Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (BRCA) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

How Is Breast Cancer Gene (BRCA) Mutations Treatment Market Demand Varying Across Different Regions?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2025, By The Business Research Company

Converted Paper Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795